<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872560</url>
  </required_header>
  <id_info>
    <org_study_id>NEEDLEN/DCD/4/I</org_study_id>
    <nct_id>NCT00872560</nct_id>
  </id_info>
  <brief_title>Comparison of 2 NovoFine® Needles on the Reflux of Insulin</brief_title>
  <official_title>Insulin Leakage and Pain Perception in IDDM Children or Adolescents, Where the Injections Are Performed With NovoFine™ 6 x 0.30 mm Needles and NovoFine® 8 x 0.30 mm Needles: An Open, Randomized, Two-period Cross-over, Multi-centre, Phase IIIb Trial at 4 Centres</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. This trial aims to ensure that there is no substantial
      clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and
      NovoFine® 8 x 0.30 mm on reflux of insulin back to the surface of cutis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 1998</start_date>
  <completion_date type="Actual">July 27, 1998</completion_date>
  <primary_completion_date type="Actual">July 27, 1998</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weighing of reflux of insulin</measure>
    <time_frame>6 seconds after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain perception</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of bleedings</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactions at injection sites</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Delivery Systems</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoFine® needle 6 mm</intervention_name>
    <other_name>NEEDLEN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoFine® needle 8 mm</intervention_name>
    <other_name>NEEDLEN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children/adolescents with type 1 diabetes mellitus

          -  Usage of NovoPen® 1.5 for at least 3 months

          -  Duration of insulin treatment more than 1 year

          -  Normal weight according to Tanner scales

          -  The means of the last 2 HbA1c measurements taken within the last 6 months must be less
             than 10.5%

        Exclusion Criteria:

          -  Pregnancy or desire to become pregnant

          -  Clinical relevant peripheral neuropathy as judged by the investigators

          -  Pronounced lipodystrophy in accordance with investigator's evaluation

          -  Use of drugs that can influence the trial

          -  Coagulation disorders (use of anti-coagulants)

          -  Serious, chronic diseases, making it highly unlikely that the subject can complete the
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

